J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION

Size: px
Start display at page:

Download "J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION"

Transcription

1 VOLUME 25 NUMBER 24 AUGUST JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, Franco Muggia, and William P. McGuire From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam; Medical Oncology, The University of Texas M.D. Anderson, Houston, TX; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, DC; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo; Departments of Medicine and Medical Oncology, Kaplan Cancer, Center, New York University Medical Center, New York, NY; Gynecologic Oncology of West Michigan, Grand Rapids, MI; Medical Science, Fox Chase Cancer Center, Philadelphia, PA; Division of Gynecologic Oncology, Case Western Reserve University; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, Cleveland, OH; Oncology, Gynecology, and Obstetrics, Johns Hopkins Kimmel Cancer Center; and the Harry and Jeanette Weinberg Cancer Institute, Franklin Square Hospital Center, Baltimore, MD. Submitted December 22, 2006; accepted May 15, Supported by National Cancer Institute grants to the Gynecologic Oncology Group administrative office (CA 27469) and statistical office (CA 37517). A B S T R A C T Purpose Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity of study population. The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC. Patients and Methods A retrospective review of demographic, pathologic, treatment, and outcome data from 1,895 patients with International Federation of Gynecology and Obstetrics stage III EOC who had undergone primary surgery followed by six cycles of intravenous platinum/paclitaxel was conducted. A proportional hazards model was used to assess the association of prognostic factors with progression-free survival (PFS) and overall survival (OS). Results Increasing age was associated with increased risks for disease progression (HR 1.06; 95% CI, 1.02 to 1.11 for an increase every 10 years) and death (HR 1.12; 95% CI, 1.06 to 1.18). Mucinous or clear-cell histology was associated with a worse PFS and OS compared with serous carcinomas. Patients with performance status (PS) 1 or 2 were at an increased risk for recurrence compared with PS 0 (HR 1.12; 95% CI, 1.01 to 1.24). Compared with patients with microscopic residual disease, patients with 0.1 to 1.0 cm and 1.0 cm residual disease had an increased risk of recurrence (HR 1.96; 95% CI, 1.70 to 2.26; and HR 2.36; 95% CI, 2.04 to 2.73, respectively) and death (HR 2.11; 95% CI, 1.78 to 2.49; P.001; and HR 2.47; 95% CI, 2.09 to 2.92, respectively). Conclusion Age, PS, tumor histology, and residual tumor volume were independent predictors of prognosis in patients with stage III EOC. These data can be used to identify patients with poor prognosis and to design future tailored randomized clinical trials. J Clin Oncol 25: by American Society of Clinical Oncology Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Address reprint requests to G. Larry Maxwell, MD, Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, DC 20307; george.maxwell@ na.amedd.army.mil by American Society of Clinical Oncology X/07/ /$20.00 DOI: /JCO INTRODUCTION The American Cancer Society (Atlanta, GA) estimates there will be 22,220 new cases of epithelial ovarian cancer (EOC) in 2005 and 16,210 diseaserelated deaths. 1 Unfortunately, the majority of patients diagnosed with ovarian cancer present with advanced stage disease. Although aggressive surgical cytoreduction and platinum/paclitaxel combination chemotherapy have resulted in improved outcomes for many ovarian cancer patients over the past decade, the long-term survival has not been uniformly improved. For this reason, identification of prognostic factors predictive of poor outcome in patients with ovarian cancer may facilitate more targeted therapeutic regimens in the future. Several factors are recognized as prognostic of clinical outcomes in patients with EOC. International Federation of Gynecology and Obstetrics stage and residual volume of tumor after primary surgical cytoreduction are the most consistently reported prognostic factors. 2-4 The Gynecologic Oncology Group (GOG) previously analyzed prognostic factors in 726 women with suboptimal stage III or IV EOC treated on two randomized phase III trials: protocols 22 and In that report, age, performance status (PS), and tumor histology were independent predictors of overall survival (OS). However, only 28% of the patients received a platinum-based regimen, and no patient received paclitaxel as part of primary therapy. Furthermore, optimal stage III patients were not included in the cohort (unlike the current study). However, the role 3621

2 Winter et al played by other factors such as age, PS, race, tumor histology, and grade has been reported in recent literature. 6-8 These conflicting results may be partially explained by small sample sizes or heterogeneity of the study population, which in combination with other confounding influences makes analysis difficult. Given the inconsistent results of recent studies, it is unclear whether these patient factors (suggesting a biologic impact that may not be overcome by therapy) have the same impact today, considering the improved progression-free survival (PFS) and OS seen with current standard paclitaxel/platinum-based chemotherapy. Also, in light of our recent analysis of prognostic factors for patients with stage IV EOC (unpublished data), separate analyses of residual disease in patients with stage III and IV EOC, as opposed to combining these groups, seemed prudent. Over the past 13 years, GOG has conducted six randomized phase III trials using chemotherapy consisting of a platinum agent and paclitaxel following primary surgical cytoreduction for advanced EOC. Using this large and similarly treated group of patients, we performed an analysis of the pooled data aimed at identifying independent prognostic factors in this population and to update PFS and OS estimates for patients with invasive EOC treated with a contemporary regimen. PATIENTS AND METHODS The current study was a retrospective review of data from patients treated with platinum and paclitaxel combination chemotherapy on one of six prospective randomized clinical trials conducted by GOG: protocols 111, 9 114, , , , 13 and With the exception of the experimental arm(s) from GOG 152 and 158, patients included in this study were treated with primary surgical cytoreduction followed by six cycles of a 24-hour infusion of intravenous paclitaxel (135 mg/m 2 ) followed by intravenous cisplatin (75 mg/m 2 ), the control arm of all six trials. We included the experimental arms of GOG 152 and 158 because these trials demonstrated statistically equivalent clinical outcomes between the control and experimental arms. Table 1 details the treatment regimens from each protocol included in this study. Details regarding eligibility criteria, treatment, and outcome for each particular study have been previously published Patients provided written informed consent consistent with all federal, state, and local requirements before receiving protocol therapy. The primary end points for all six studies were disease recurrence, PFS, and OS. PFS was calculated from the date of study enrollment to the date of disease recurrence, death, or most recent follow-up visit. OS was calculated from the date of study enrollment to the date of death or last contact. Laboratory and clinical data were collected at specified intervals per protocol. Patients were divided into three groups for analysis, based on residual disease status: microscopic, 0.1 to 1.0 cm, and 1.0 cm. Clear-cell carcinomas were assigned grade 3. Baseline PS before initiating chemotherapy was defined according to GOG criteria as 0 for normal activity, 1 for symptomatic and fully ambulatory, and 2 for symptomatic and in bed less than 50% of the time. Cox proportional hazards model was used to assess the association between the clinical and pathologic factors, and disease progression and survival. The logarithm of the hazard versus logarithm of the time curve was used to validate the model assumption of proportional hazards. Multivariate analysis was then conducted to identify the independent prognostic factors as well as to estimate their effects on PFS and OS adjusted for covariates (age group, race, PS, histology, tumor grade, and residual disease). Kaplan-Meier survival curves by clinical characteristics were calculated and compared using the log-rank test. All statistical tests were two-tailed with a significance level set at 5%. All statistical analyses were performed using Statistical Analysis Software version 9.1 (SAS Institute, Cary, NC). RESULTS Data from 1,895 patients with stage III invasive EOC who underwent primarysurgicalcytoreductionfollowedbypaclitaxel/platinumchemotherapy, while participating in one of six GOG clinical trials (Table 1), was analyzed for the present study. Table 2 summarizes the demographic and clinical characteristics of the study population. The median age was 57 years (range, 16 to 86 years), 88% were white, and 59% had a baseline PS 1 or 2. Twenty-three percent had no visible disease, 42% had 0.1 to 1.0 cm tumor residual, and 35% had a tumor residual of 1.0 cm after surgical cytoreduction. Seventy-four percent of patients had serous histology, and 53% had poorly differentiated tumors. One thousand five hundred five recurrences and 1,323 deaths were identified during a median follow-up period of 43 months. Overall, the median PFS was 17.1 months (95% CI, 16.4 to 17.8 months), and the median OS was 45.3 months (95% CI, 43.0 to 47.7 months). Table 1. GOG Protocols and Study Populations GOG Protocol No. Patient Eligibility Treatment Regimen Eligible No. of Patients Suboptimal ( 1-cm residual), stage III/IV EOC IV paclitaxel 135 mg/m 2, cisplatin 75 mg/m 2, Optimal ( 1-cm residual), stage III EOC IV paclitaxel 135 mg/m 2, cisplatin 75 mg/m 2, Suboptimal ( 1-cm residual), stage III/IV EOC IV paclitaxel 135 mg/m 2, cisplatin 75 mg/m 2, Suboptimal ( 1-cm residual), stage III EOC IV paclitaxel 135 mg/m 2, cisplatin 75 mg/m 2, interval debulking Optimal ( 1-cm residual), stage III EOC IV paclitaxel 135 mg/m 2 (24 hours), cisplatin 75 mg/m 2, or IV paclitaxel 175 mg/m 2 (3 hours), carboplatin AUC 7.5, Optimal ( 1-cm residual), stage III EOC/PSPC IV paclitaxel 135 mg/m 2, cisplatin 75 mg/m 2, Abbreviations: GOG, Gynecologic Oncology Group; EOC, epithelial ovarian cancer; IV, intravenously; AUC, area under the curve; PSPC, papillary serous. Patients with stage IV disease were not eligible for this study JOURNAL OF CLINICAL ONCOLOGY

3 Prognostic Factors in Ovarian Cancer Characteristic Table 2. Patient Characteristics (N 1,895) No. of Patients % Age, years Median 57 Range Race White 1, African American Other GOG performance status Tumor grade Histology Serous 1, Endometrioid Clear cell Mucinous Mixed epithelial Adenocarcinoma unspecified Undifferentiated Other Residual disease Microscopic cm cm Abbreviation: GOG, Gynecologic Oncology Group. Univariate Analysis Table 3 shows median PFS and OS based on patient characteristics. Increasing age was associated with decreased PFS and OS. Median PFS and OS were shorter for patients with a PS of 1 or 2 when compared with those with a PS of 0. No difference in median PFS was evident between PS 1 and PS 2 patients, whereas the difference in median OS between the same groups was observed. Based on tumor histology, patients with endometrioid histology had improved clinical outcomes compared with those with serous tumors. Patients with mucinous or clear-cell tumors had decreased PFS and OS. Patients with mucinous cell type had a median OS of only 15 months compared with 24, 45, and 56 months for clear-cell, serous, and endometrioid cell types, respectively (Fig 1A and 1B). These results were further demonstrated by multivariate analysis below. Patients with microscopic residual disease had the longest PFS and OS 33 and 72 months, respectively compared with patients with any gross residual disease. The differences in median PFS and OS between the 0.1 to 1.0 cm and 1.0 cm residual disease groups were also evident, albeit small (3 months in median PFS and 7 months in median OS; Fig A1, online only). Patients with grade 2 or 3 tumors were associated with decreased PFS and OS. Race was not significantly associated with PFS or OS. Table 3. Median Progression-Free Survival and Overall Survival by Patient Characteristics Characteristic No. of Patients Multivariate Regression Analysis All variables considered as potential prognostic factors were included in a Cox proportional hazards regression model to identify independent prognostic factors, the results of which are illustrated in Table 4. Increasing age was linearly associated with increased risk of disease progression and death. When age was reanalyzed as a continuous variable, an interval increase of 10 years was estimated to lead to a6%(hr 1.06; 95% CI, 1.02 to 1.11; P.008) increased risk for disease progression and a 12% (HR 1.12; 95% CI, 1.06 to 1.18; P.001) increased risk for death (Fig 2). Patients whose GOG PS was 1 or 2 had an increased risk of disease progression (HR 1.12; 95% CI, 1.01 to 1.24; P.03) compared with those with a PS of 0. Results were similar for OS. When compared with serous histology, mucinous (HR 2.18; 95% CI, 1.48 to 3.22; P.001) and clear-cell (HR 1.37; 95% CI, 1.01 to 1.85; P.04) histology were associated with a decreased PFS. Results were similar for OS. Using the same referent, patients with endometrioid histology demonstrated a significantly better PFS (HR 0.76; 95% CI, 0.64 to 0.92; P.004) and OS (HR 0.79; 95% CI, 0.65 to 0.97; P.02). Using microscopic residual disease as the referent, the hazard ratio for disease progression PFS Median (months) P OS Median (months) Age group, years Race White African American Other GOG performance Histology Serous Endometrioid Clear cell Mucinous Mixed epithelial Adenocarcinoma unspecified Undifferentiated Other Tumor grade Disease residual Microscopic cm cm Abbreviations: PFS, progression-free survival; OS, overall survival; GOG, Gynecologic Oncology Group. P

4 Winter et al A PFS Probability B OS Probability Time on Study (months) Time on Study (months) in patients with 0.1 to 1.0 cm and 1.0 cm was 1.96 (95% CI, 1.70 to 2.26; P.001) and 2.36 (95% CI, 2.04 to 2.73; P.001), respectively. OS also was decreased for patients with 0.1 to 1.0 cm (HR 2.11; 95% CI, 1.78 to 2.49; P.001) and 1.0 cm (HR 2.47; 95% CI, 2.09 to 2.92; P.001) residual disease compared with those with only microscopic residual disease. Neither tumor grade nor race was independently associated with clinical outcomes. DISCUSSION NP P Total Serous 199 1,193 1,392 Endometrioid Clear cell Mucinous Alive Dead Total Serous ,392 Endometrioid Clear cell Mucinous Fig 1. (A) Estimated progression-free survival (PFS) by histology. Adjusted relative risk of disease progression for endometrioid, clear-cell, and mucinous cell type as compared with serous cell type was 0.76 (95% CI, 0.64 to 0.92; P.004), 1.37 (95% CI, 1.01 to 1.85; P.04), and 2.18 (95% CI, 1.48 to 3.22; P.001), respectively. There is a suggestion that mucinous cell type was also at increased risk for disease progression compared with clear-cell type (HR 1.59; 95% CI, 0.98 to 2.59; P.06). (B) Estimate of overall survival (OS) by histology. OS probability adjusted relative risk of death for endometrioid, clear-cell, and mucinous cell type as compared with serous cell type was 0.79 (95% CI, 0.65 to 0.97; P.02), 1.74 (95% CI, 1.26 to 2.41; P.001), and 4.14 (95% CI, 2.77 to 6.19; P.001), respectively. Relative risk of mucinous v clear-cell type was 2.38 (95% CI, 1.43 to 3.95; P.001). NP, no progression; P, progression. This study represents a retrospective analysis of a large group of patients with stage III EOC who received primary cytoreduction and intravenous platinum and paclitaxel chemotherapy during participation in a GOG trial. Although the prognostic factors identified in this study have been reported, the conclusions of these studies are inconsistent and have included heterogeneous patient populations that were treated with dissimilar nonpaclitaxel-based adjuvant chemotherapy. 3,4,15,16 In the current study, age, PS, tumor histology, and residual disease volume were statistically significant prognostic factors in the multivariate analysis. The strength of our study compared with previous reports is the size and similarity of the population, which confers enhanced statistical power to detect independent variables predictive of poor outcome and, more important, to provide a precise estimation of the magnitude of the effect while controlling for confounding influences, which would otherwise make these results less generalizable. Recent investigations have evaluated the relationship between age at diagnosis of ovarian cancer and prognosis. In general, younger patients have a higher frequency of borderline and well-differentiated invasive EOC. Patients younger than 30 to 40 years present with early-stage disease more than half of the time 8,17-22 and are more likely to be optimally cytoreduced when compared with those older than 40 years. 8,17 An analysis of 18,191 patients (2,560 patients 45 years old) in the Surveillance, Epidemiology, and End Results Program 18 with either borderline or invasive EOC, who were treated with a wide variety of chemotherapy, radiotherapy, and surgical procedures, demonstrated that 5-year OS was improved for patients younger than 45 years (45%) compared with those older than 85 years. However, the analysis did not control for variables such as type of therapy, borderline tumors, stage of disease, residual disease after cytoreduction, or comorbidities. A descriptive study 17 of 2,123 patients with invasive EOC from GOG protocols 22, 25, 47, 52, 60, and 97 reported that patients older than 69 years exhibited poorer survival even after adjusting for residual disease, tumor grade, PS, and stage. Although four of the six protocols included cisplatin in at least one treatment arm, there were a total of 13 different chemotherapy regimens, and none included paclitaxel. Nonetheless, the study suggested that survival among ovarian cancer patients might differ according to age. Our data suggest that older women are at increased risk of recurrence and death. Differences in tumor biology, immune response, and comorbidities may explain the poorer prognosis in elderly patients. In addition, many providers may be hesitant to treat older patients aggressively (particularly with salvage therapies), and this reluctance potentially could have contributed to the linear relationship between age and progression. However, an analysis of age and the proportion of patients completing their chemotherapy regimen revealed that only patients older than 70 years (14% of the total) in our study had an associated decrease in the number of individuals completing six cycles of treatment. Patients older than 70 years completed 77% of planned cycles. The association between poor PS and decreased PFS and OS has been previously described. 6,23-25 In the studies included in our report, a PS of 0 to 2 was an eligibility criterion. Our analysis showed that PS was an independent predictor of recurrence and survival, even without PS 3 and 4 patients. Some investigators have suggested that PS should determine treatment in elderly patients with EOC. Data from the National Cancer Institute (Bethesda, MD) have demonstrated that elderly patients with good PS tolerate the same level of dose-intensive platinum therapy as younger patients. 26 Previous studies have inconsistently described the relationship between tumor histology and prognosis. One study found that tumor histology in stage III and IV EOC was not an independent predictor of clinical outcome. 7 In contrast, a study of stage IV EOC found that patients with mucinous and clear-cell histologies had a worse OS 3624 JOURNAL OF CLINICAL ONCOLOGY

5 Prognostic Factors in Ovarian Cancer Table 4. Multivariate Analysis of Prognostic Factors Characteristic Disease Progression Death HR 95% CI P HR 95% CI P Age, years to to to to to to to to Race White African American to to Other to to GOG performance status to to to to Histology Serous Endometrioid to to Clear cell to to Mucinous to to Mixed epithelial to to Adenocarcinoma to to unspecified Undifferentiated to to Other to to Tumor grade to to to to Residual disease Microscopic cm to to cm to to Abbreviations: HR, hazard ratio; GOG, Gynecologic Oncology Group. With every 10 years of increase, HR 1.06 (95% CI, 1.02 to 1.11; P.008) for disease progression and HR 1.12 (95% CI, 1.06 to 1.18; P.001) for death. For performance status 1 and 2 v performance status 0, HR 1.12 (95% CI, 1.01 to 1.24; P.03) for disease progression. relative to those with serous tumors. 6 More recently, a small study of EOC, in which mucinous histology was compared with matched controls of other histologies, found a significantly decreased PFS and OS in patients with mucinous histology. 27 The current study suggests that mucinous and clear-cell carcinomas are associated with a worse PFS and OS when compared with serous histology. Clear-cell histology has been generally accepted as an unfavorable histology. Further, recent microarray experiments have revealed that clear-cell carcinoma has a genomic expression pattern that differs from serous epithelial ovarian cancers, suggesting that the biologic phenotype of the clear-cell subtype is unique. 28 In the current study, mucinous histology was associated with almost twice the risk of death relative to clear-cell histology. Because mucinous carcinoma of the ovary is rare, our understanding of its molecular alterations is limited. However, its associated poor prognosis suggests a more aggressive biologic activity. Although tumor specimens collected from participants in the six trials were reviewed centrally by the GOG Pathology Committee to confirm the diagnosis, it is possible that some of the mucinous tumors may have been primary colon cancers with metastasis to the ovary. No pretreatment assessment of the gastrointestinal tract was required by protocol. Some investigators have suggested that 7% of ovarian cancers may actually be metastatic, with the majority representing extension from a gastrointestinal primary. 29,30 An inaccurate diagnosis of a gastrointestinal carcinoma as a mucinous ovarian primary would result in inappropriate adjuvant chemotherapy. Recent genomic and proteomic high-throughput array experiments have identified markers that may assist in distinguishing ovarian and primary colon cancers in the future. 31 Although tumor grade is a significant prognostic variable in early-stage EOC, 32 it does not appear to be a predictor of poor outcome advanced disease. 33,34 Investigators have suggested that the response to surgical cytoreduction is not significantly affected by tumor grade. 35 Also, responsiveness to platinum-based chemotherapy in International Collaborative Ovarian Neoplasm Collaborators trial 3 was not associated with tumor grade. 36 In the current study, grade was not an independent predictor of outcome. This conclusion did not change even when clear-cell cancers were designated as grade 3 and included in the model. The median survival for African Americans with advanced EOC is nearly 1 year less than that of white women (22 v 32 months; P.0001). 37 Data from the National Cancer Data Base has revealed that the racial disparity in outcome is particularly evident for patients

6 Winter et al Log(HR) Progression Death treated with the current standard therapy of primary cytoreductive surgery followed by intravenous platinum/paclitaxel chemotherapy. It would appear that the magnitude of improvement in PFS and OS provided by the addition of taxanes to adjuvant therapy is not large enough to abrogate the impact of these prognostic factors. Residual tumor size continues to be an important prognostic factor, especially when all macroscopic disease is removed. Although translational research is important in determining whether these results are due to tumor biology and unaffected by improved therapy, future study designs might incorporate stratifications based on these independent predictors of PFS and OS as has been recommended previously < Age Group (years) Fig 2. Assessment of association of age with clinical outcomes adjusted for covariates. Increasing every 10 years in age was associated with a 6% increase in risk for disease progression (95% CI, 2% to 11%; P.008) and a 12% increase in risk for death (95% CI, 6% to 18%; P.001). with stage III disease. Further, the 5-year survival rate for African Americans is 18% versus 29% for white women. 38 Reports from both the NCDB 38 and the population-based SEER Program 39 have indicated that African American women are less likely to receive aggressive therapy and are more likely to be treated with chemotherapy alone than with a combination of surgery and chemotherapy. The current study involved women who were treated with a standardized regimen of primary surgical cytoreduction followed by adjuvant paclitaxel and platinum chemotherapy, irrespective of race. There were no differences in PFS and OS between white and African American patients in multivariate regression analyses. Our results suggest that when patients are treated on protocol requiring equivalent care according to a regimented algorithm, the disparity in outcome between races is not apparent. Patients in the current study with microscopic residual disease have a far better PFS and OS than previously reported for optimal cohorts, which included patients with 1.0 cm of residual disease, including microscopic residual disease. As with previous studies, patients with gross residual disease 1.0 cm had improved clinical outcomes compared with those with gross residual disease 1.0 cm. Further detailed analysis of an association between varying degrees of residual disease volume and clinical outcome is warranted. In conclusion, increasing age, impaired PS, and mucinous or clear-cell histology, and gross residual disease are all independent predictors of decreased PFS and OS in patients with stage III EOC AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment: N/A Leadership: N/A Consultant: Robert F. Ozols, Bristol-Myers Squibb Co, Eli Lilly & Co, Novartis Inc, Genentech, GlaxoSmithKline, Telik Inc, Unither Pharmaceuticals; Franco Muggia, Bristol-Myers Squibb Co, Ortho Biotech Stock: Robert F. Ozols, Celgene, Pfizer, Biogenidex Honoraria: Robert F. Ozols, Eli Lilly & Co, Bristol-Myers Squibb Co; Franco Muggia, Ortho Biotech Research Funds: Franco Muggia, Roche, Bristol-Myers Squibb Co Testimony: N/A Other: N/A AUTHOR CONTRIBUTIONS Conception and design: William E. Winter III, G. Larry Maxwell, Jay W. Carlson Provision of study materials or patients: Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, William P. McGuire Collection and assembly of data: William E. Winter III, Chunqiao Tian, Deborah K. Armstrong, Franco Muggia, William P. McGuire Data analysis and interpretation: William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Maurie Markman, Deborah K. Armstrong, William P. McGuire Manuscript writing: William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson Final approval of manuscript: William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, Franco Muggia, William P. McGuire REFERENCES 1. Jemal A, Murray T, Ward E, et al: Cancer statistics CA Cancer J Clin 55:10-30, Ng LW, Rubin S, Hoskins WJ, et al: Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 38: , Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: , Hoskins WJ, Bundy BN, Thigpen T, et al: The influence of cytoreduction surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47: , Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9: , Akahira JI, Yoshikawa H, Shimizu Y, et al: Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol 81: , Chi DS, Liao JB, Leon LF, et al: Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: , Duska LR, Chang YC, Flynn CE, et al: Epithelial ovarian carcinoma in the reproductive age group. Cancer 85: , McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). N Engl J Med 334: 1-6, Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, 3626 JOURNAL OF CLINICAL ONCOLOGY

7 Prognostic Factors in Ovarian Cancer and Eastern Cooperative Oncology Group. J Clin Oncol 19: , Muggia F, Braly P, Brady M, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 18: , Rose PG, Nerenstone SR, Brady MF, et al: A randomized trial of secondary surgical cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. N Engl J Med 351: , Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21: , Armstrong D, Bundy BN, Walker J, et al: A phase III randomized trial of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in patients with optimal stage III epithelial ovarian carcinoma or primary peritoneal carcinoma. N Engl J Med 354:34-43, Lund B, Wiliamson P, van Houwelingen HC, et al: Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 50: , Marsoni S, Torri V, Balsecchi MG, et al: Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 62: , Thigpen T, Brady MF, Omura GA, et al: Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience. Cancer 71: , 1993 (suppl 2) 18. Ries LA: Ovarian cancer. Survival and treatment differences by age. Cancer 71: , 1993 (suppl 2) 19. Massi D, Susini T, Savino L, et al: Epithelial ovarian tumors in the reproductive age group: Age is not an independent prognostic factor. Cancer 77: , Plaxe SC, Braly PS, Freddo JL, et al: Profiles of women age and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 81: , Rodriguez M, Nguyen HN, Averette HE, et al: National survey of ovarian carcinoma XII: Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 73: , Tsai JY, Saigo PE, Brown C, et al: Diagnosis, pathology, staging, treatment, and outcome of epithelial ovarian neoplasia in patients age 21 years. Cancer 91: , Clark TG, Stewart ME, Altman DG, et al: A prognostic model for ovarian cancer. Br J Cancer 85: , Gronlund B, Hogdall C, Hansen HH, et al: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94: , Chan JK, Loizzi V, Lin YG, et al: Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important. Obstet Gynecol 102: , Cornelison TL, Reed E: Dose intensity analysis of high-dose carboplatin in refractory ovarian cancer relative to age. Cancer 71: , Hess V, A Hern R, Nasiri N, et al: Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol 22: , Zorn KK, Awtrey CS, Gardner GJ, et al: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Gynecol Oncol 88:A90, Daya D, Nazerali L, Frank GL: Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma. Am J Clin Pathol 97: , Gersell DJ: Metastatic ovarian tumors: Still a challenge. Am J Clin Oncol 97: , Nishizuka S, Chen ST, Gwadry FG, et al: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: , Vergote I, Brabanter JD, Fyles A, et al: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357: , Hoskins WJ, Rubin SC, Dulaney E, et al: Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 34: , Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72: , van der Burg MEL, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian cancer. N Engl J Med 332: , The International Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomized trial. Lancet 360: , Barnholtz-Sloan JS, Tainsky MA, Abrams J, et al: Ethnic differences in survival among women with ovarian carcinoma. Cancer 94: , Parham G, Phillips JL, Hicks ML, et al: The National Cancer Institute data base report on epithelial ovarian carcinoma in African-American women. Cancer 80: , Harlan LC, Clegg TX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21: , 2003 Acknowledgment The Acknowledgment is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader ). Appendix The Appendix is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader )

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 1 JANUARY 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer:

More information

CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers

CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study Chunqiao Tian, MS 1, Maurie Markman,

More information

Current state of upfront treatment for newly diagnosed advanced ovarian cancer

Current state of upfront treatment for newly diagnosed advanced ovarian cancer Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute

More information

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology

More information

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common

More information

ACRIN Gynecologic Committee

ACRIN Gynecologic Committee ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic

More information

Side Effects. PFS (months) Study Regimen No. patients. OS (months)

Side Effects. PFS (months) Study Regimen No. patients. OS (months) Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped

More information

Original Research. Background

Original Research. Background Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,

More information

PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC

PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy

More information

Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009

Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009 Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types

More information

Clinical Trials. Ovarian Cancer

Clinical Trials. Ovarian Cancer 1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric

More information

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan

More information

CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?

CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA? CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA? M. Modarres-Gilani *1, F. Ghaemmaghami 1, S. Ansaripoor 1, M. Shariat 2 and F. Zaeri 3 1)

More information

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer Original Article J Gynecol Oncol Vol. 22, No. 4:269-274 pissn 2005-0380 eissn 2005-0399 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian

More information

Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer

Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal

More information

Prof. Dr. Aydın ÖZSARAN

Prof. Dr. Aydın ÖZSARAN Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid

More information

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer The new england journal of medicine original article Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Deborah K. Armstrong, M.D., Brian Bundy, Ph.D., Lari Wenzel, Ph.D., Helen Q. Huang, M.S.,

More information

AHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following

AHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked

More information

Introduction. Abstract

Introduction. Abstract Gynecologic Oncology 103 (2006) 1083 1090 www.elsevier.com/locate/ygyno The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC

More information

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David

More information

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17 OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay

More information

BACKGROUND. The objective of this study was to determine the impact of malignant

BACKGROUND. The objective of this study was to determine the impact of malignant 1397 The Clinical Significance of Malignant Pleural Effusions in Patients with Optimally Debulked Ovarian Carcinoma Ram Eitan, M.D. Douglas A. Levine, M.D. Nadeem Abu-Rustum, M.D. Yukio Sonoda, M.D. Jae

More information

Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany

Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences

More information

Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG

Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Original Investigation 33 Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Gökhan Boyraz, Derman Başaran, Mehmet

More information

PROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER FOLLOWED BY COMPLETE REMISSION AFTER ADJUVANT CHEMOTHERAPY

PROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER FOLLOWED BY COMPLETE REMISSION AFTER ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Obstet Gynecol Sci 2013;56(1):29-35 http://dx.doi.org/10.5468/ogs.2013.56.1.29 pissn 2287-8572 eissn 2287-8580 PROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN

More information

Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report

Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report ONCOLOGY LETTERS 9: 1239-1243, 2015 Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report SHIGAO HUANG *, YAZHENG

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096

More information

Trial record 1 of 1 for:

Trial record 1 of 1 for: Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,

More information

Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,

More information

Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa

Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal

More information

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:

More information

Cancer Cell Research 19 (2018)

Cancer Cell Research 19 (2018) Available at http:// www.cancercellresearch.org ISSN 2161-2609 LncRNA RP11-597D13.9 expression and clinical significance in serous Ovarian Cancer based on TCGA database Xiaoyan Gu 1, Pengfei Xu 2, Sujuan

More information

breast and OVARIAN cancer

breast and OVARIAN cancer breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death

More information

RESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods

RESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*

More information

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single

More information

Original Article. Management of Ovarian Cancer: Experience of a single Institution. Elkhouly. E.¹, Abdelghany. A.¹, Rageh. T. 2 and Shehata. M.

Original Article. Management of Ovarian Cancer: Experience of a single Institution. Elkhouly. E.¹, Abdelghany. A.¹, Rageh. T. 2 and Shehata. M. Original Article Kasr El-aini J. Clin. Oncol. nucl. med. vol. 10, no. 1-2, Jan.-April. 2014:12-17 Management of Ovarian Cancer: Experience of a single Institution Elkhouly. E.¹, Abdelghany. A.¹, Rageh.

More information

The effect of delayed adjuvant chemotherapy on relapse of triplenegative

The effect of delayed adjuvant chemotherapy on relapse of triplenegative Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,

More information

Hitting the High Points Gynecologic Oncology Review

Hitting the High Points Gynecologic Oncology Review Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and

More information

The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology

The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University

More information

Chibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article

Chibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article Original Article Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile

More information

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma original article Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma Peter G. Rose, M.D., Stacy Nerenstone, M.D., Mark F. Brady, Ph.D., Daniel Clarke-Pearson, M.D., George Olt, M.D., Stephen

More information

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy MICHAEL A. BOOKMAN Medical Gynecologic Oncology, Medical Information Management, Department

More information

Ovarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?

Ovarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress? Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial

More information

Gynecologic Oncology

Gynecologic Oncology Gynecologic Oncology 124 (2012) 10 14 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno An analysis of patients with bulky advanced

More information

Surgical Cytoreduction in Ovarian Cancer

Surgical Cytoreduction in Ovarian Cancer Review Article [1] May 01, 2004 Ovarian Cancer [2], Oncology Journal [3] By Wayne A. Mccreath, MD [4] and Dennis S. Chi, MD [5] The majority of ovarian cancer patients present with advanced-stage disease,

More information

Johns Hopkins University, Baltimore, Maryland, USA. 1. Better appreciate the challenges faced in managing treatment of patients with ovarian cancer.

Johns Hopkins University, Baltimore, Maryland, USA. 1. Better appreciate the challenges faced in managing treatment of patients with ovarian cancer. The Oncologist Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease DEBORAH K. ARMSTRONG Johns Hopkins University, Baltimore, Maryland, USA Key Words. Chronic disease Ovarian

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Ovarian cancer in elderly women

Ovarian cancer in elderly women Ovarian cancer Ovarian cancer in elderly women Claire FALANDRY, Michel FABBRO, Olivier GUERIN, Jean-Emmanuel KURTZ, Anne LESOIN. Problem Background Population on the rise and extremely heterogeneous Delayed

More information

1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian

1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian 1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38(18):2435-45.

More information

State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011

State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center Ovarian Cancer 21,880 new cases

More information

INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for

INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for more deaths than both cervical and endometrial tumours.

More information

Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz

Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz Epithelial Subtypes Serous Endometrioid Mucinous Transitional Clear Cell Mixed Undifferentiated Squamous Ovarian Surface Epithelium Naora et al.,

More information

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1

More information

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man

More information

Anshuma Bansal 1 Bhavana Rai

Anshuma Bansal 1 Bhavana Rai DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional

More information

Tumor Characteristics in Blacks and Whites

Tumor Characteristics in Blacks and Whites Tumor Characteristics in Blacks and Whites with Endometrial Cancer Larry Maxwell, M.D. Chairman, Dept of OB-GYN at Inova Fairfax Hospital Co-Director, GYN Cancer Center of Excellence Professor, Virginia

More information

Survival impact of cytoreductive surgery ın advanced stage EOC

Survival impact of cytoreductive surgery ın advanced stage EOC Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER

More information

Hyponatremia in small cell lung cancer is associated with a poorer prognosis

Hyponatremia in small cell lung cancer is associated with a poorer prognosis Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,

More information

Controversies in the Management of Advanced Ovarian Cancer

Controversies in the Management of Advanced Ovarian Cancer 안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking

More information

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:

More information

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer Xu et al. Journal of Ovarian Research (2016) 9:85 DOI 10.1186/s13048-016-0294-z RESEARCH Open Access Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage

More information

Hongfei Gao 1, Lijun Yuan 2 and Yimin Han 1*

Hongfei Gao 1, Lijun Yuan 2 and Yimin Han 1* Gao et al. World Journal of Surgical Oncology (2016) 14:168 DOI 10.1186/s12957-016-0930-5 RESEARCH Open Access Comparisons of the survival time of patients with ovarian cancer adopting postoperative chemotherapy

More information

Women s Imaging Original Research

Women s Imaging Original Research Women s Imaging Original Research Lakhman et al. Postoperative CT as Prognostic Biomarker in Gynecologic Cancer Women s Imaging Original Research Yulia Lakhman 1 Oguz Akin 1 Michael J. Sohn 1 Junting Zheng

More information

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer 412 Clin Oncol Cancer Res (2009) 6: 412-417 DOI 10.1007/s11805-009-0412-4 Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent

More information

Introduction to REMARK: Reporting tumour marker prognostic studies

Introduction to REMARK: Reporting tumour marker prognostic studies Introduction to REMARK: Reporting tumour marker prognostic studies Doug Altman The EQUATOR Network Centre for Statistics in Medicine, Oxford, UK C 1 S M Reliable research Reliability is determined by proper

More information

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following

More information

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis Davidson et al. Gynecologic Oncology Research and Practice (2016) 3:13 DOI 10.1186/s40661-016-0032-7 RESEARCH Open Access Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma:

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage

Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures

More information

Surveillance report Published: 17 March 2016 nice.org.uk

Surveillance report Published: 17 March 2016 nice.org.uk Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for

More information

International Society of Gynecological Pathologists Symposium 2007

International Society of Gynecological Pathologists Symposium 2007 International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade

More information

symposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article

symposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article Annals of Oncology 27 (Supplement 1): i58 i62, 2016 doi:10.1093/annonc/mdw088 Optimal primary therapy of ovarian cancer M. A. Bookman* Arizona Oncology and US Oncology Research, Tucson, AZ, USA Background:

More information

Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies

Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies NCI Clinical Announcement Intraperitoneal chemotherapy for ovarian cancer Background Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies in the developed world. In

More information

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department

More information

GCIG Rare Tumour Brainstorming Day

GCIG Rare Tumour Brainstorming Day GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial

More information

Ovarian cancer experience from a Romanian regional center: preliminary results

Ovarian cancer experience from a Romanian regional center: preliminary results Human & Veterinary Medicine International Journal of the Bioflux Society OPEN ACCESS Research Article Ovarian cancer experience from a Romanian regional center: preliminary results 1 Anita-Roxana Maxim,

More information

RESEARCH COMMUNICATION

RESEARCH COMMUNICATION RESEARCH COMMUNICATION Clinicopathologic Analysis of Women with Synchronous Primary Carcinomas of the Endometrium and Ovary: 10- Year Experience from Chiang Mai University Hospital Jiraprapa Natee 1 *,

More information

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care

HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care Ovarian cancer Worldwide, ovarian cancer is the second leading cancer in women and the fourth common cause of

More information

Histology: Its Influence on Therapeutic Decision Making

Histology: Its Influence on Therapeutic Decision Making Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC

More information

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian

More information

Intraperitoneal Therapy for Ovarian Cancer

Intraperitoneal Therapy for Ovarian Cancer Intraperitoneal Therapy for Ovarian Cancer David S. Alberts Mary C. Clouser Lisa M. Hess (Editors) Intraperitoneal Therapy for Ovarian Cancer David S. Alberts University of Arizona College of Medicine

More information

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Ovarian Cancer in Elderly Women

Ovarian Cancer in Elderly Women Review Article [1] August 01, 2003 By Nicholas C. Lambrou, MD [2] and Robert E. Bristow, MD [3] The incidence of ovarian carcinoma increases with advancing age, peaking during the 7th decade of life and

More information

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

More information

Clinico-Epidemiological Study of Epithelial Ovarian Cancer Mansoura Experience

Clinico-Epidemiological Study of Epithelial Ovarian Cancer Mansoura Experience Cancer Research Journal 2018; 6(4): 118-125 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20180604.12 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Clinico-Epidemiological Study of

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

Analysis of the outcome of young age tongue squamous cell carcinoma

Analysis of the outcome of young age tongue squamous cell carcinoma Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of

More information

GOG-172: Survival Outcomes

GOG-172: Survival Outcomes CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142

More information

Biomarker for Response and Resistance in Ovarian Cancer

Biomarker for Response and Resistance in Ovarian Cancer 2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center

More information

Adjuvant Chemotherapy

Adjuvant Chemotherapy State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant

More information